European patients: LUME-Lung 1
In an exploratory analysis of overall survival (OS) in European patients with adenocarcinoma, median OS was increased by 4.7 months in patients treated with nintedanib* compared with those treated with placebo.1
OS outcomes for European adenocarcinoma patients in LUME-Lung 1
CI, confidence interval; HR, hazard ratio.
TSFLT as a clinical marker: LUME-Lung 1 and LUME-Lung 2
There is a lack of validated clinical or molecular markers that can predict survival benefit from anti-angiogenic treatment in non-small cell lung cancer. Predictive and prognostic markers related to nintedanib* treatment were investigated using data from the LUME-Lung 1 trial.2 TSFLT was identified as a predictive clinical marker; patients with a shorter TSFLT (<9 months) derived a greater clinical benefit from nintedanib vs placebo than patients who had TSFLT ≥9 months:
TSFLT could be used to guide treatment choice and select patients who are likely to derive the most benefit from nintedanib treatment.3
Prior treatment: LUME-Lung 1
The efficacy of nintedanib, and in particular OS, was maintained in adenocarcinoma patients in LUME-Lung 1 regardless of whether patients had received first-line treatment with bevacizumab, pemetrexed or taxanes.4
OS outcomes by prior treatment in LUME-Lung 1 adenocarcinoma patients
CI, confidence interval; HR, hazard ratio.
Fast-progressing tumors in adenocarcinoma patients: LUME-Lung 1
Further analyses of the LUME-Lung 1 study population have identified further subgroups of adenocarcinoma patients who received significant survival benefit from nintedanib treatment compared with placebo: patients with progressive disease as best response to first-line therapy (median OS difference of 3.5 months), and patients with time from end of first-line therapy (TEFLT) ≤6 months (median OS difference of 3.1 months).5
OS for adenocarcinoma patients with time from end of first-line therapy ≤6 months
CI, confidence interval; HR, hazard ratio.
OS for adenocarcinoma patients with progressive disease as best response to first-line therapy
CI, confidence interval; HR, hazard ratio.
Gottfried M, et al. Target Oncol 2017;12(4):475–85.
Gaschler-Markefski B, et al. ESMO Open 2017;11;2(1):e000102.
Reck M, et al. Future Oncol 2019;15(12):1363–83.
Heigener D, et al. J Thorac Oncol 2015;10(9 Suppl. 2):S323–S4.
Heigener D, et al. Ann Oncol 2016;27(Suppl. 6):1276P.
*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumor histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.
© 2020 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: August 2020
